Michael Mahoney Buys 186,240 Shares of Boston Scientific (NYSE:BSX) Stock

Boston Scientific Corporation (NYSE:BSX) CEO Michael Mahoney bought 186,240 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were acquired at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the transaction, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Boston Scientific Stock Performance

Shares of NYSE BSX traded down $1.36 during mid-day trading on Wednesday, reaching $47.73. 16,431,617 shares of the company’s stock were exchanged, compared to its average volume of 18,405,885. The firm has a 50-day moving average price of $45.78 and a two-hundred day moving average price of $61.39. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The firm has a market capitalization of $70.94 billion, a price-to-earnings ratio of 19.32, a price-to-earnings-growth ratio of 1.06 and a beta of 0.56. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.36%. The company had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same quarter in the prior year, the business earned $0.75 earnings per share. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific declared that its board has authorized a share buyback plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s leadership believes its shares are undervalued.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of BSX. FWL Investment Management LLC bought a new stake in Boston Scientific during the 2nd quarter valued at $26,000. Swiss RE Ltd. bought a new position in shares of Boston Scientific in the fourth quarter worth $26,000. Garton & Associates Financial Advisors LLC bought a new position in shares of Boston Scientific in the fourth quarter worth $26,000. Sfam LLC purchased a new position in shares of Boston Scientific in the fourth quarter valued at $29,000. Finally, Eagle Bay Advisors LLC purchased a new position in shares of Boston Scientific in the fourth quarter valued at $30,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Canaccord Genuity Group dropped their price objective on Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research report on Sunday. Barclays lowered their target price on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a research note on Thursday, May 28th. Truist Financial cut their price target on Boston Scientific from $62.00 to $57.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Finally, TD Cowen decreased their price objective on Boston Scientific from $61.00 to $56.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.